<DOC>
	<DOCNO>NCT01551381</DOCNO>
	<brief_summary>The principal objective study evaluate safety tolerability repeat dose EV-077-3201-2TBS give diabetic subject 4 week treatment period . The secondary aim initial Phase IIa study evaluate effect multiple oral dos EV-077-3201-2TBS platelet function , vascular function , vascular inflammation , vascular oxidative stress , renal function selection exploratory parameter biomarkers type 2 diabetic subject , well multiple dose pharmacokinetics diabetic subject . In order ensure safety diabetic subject , initial part study evaluate safety tolerability EV-077-3201-2TBS . In Part A , safety different dose EV-077-3201-2TBS investigate healthy subject treat 4 week . In parallel , Part B investigate potential interaction EV-077-3201-2TBS ASA healthy subject . Part C investigate safety , pharmacokinetics pharmacodynamics EV-077-3201-2TBS type 2 diabetic subject without concomitant ASA therapy .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics Pharmacodynamics EV-077 Type 2 Diabetic Subjects</brief_title>
	<detailed_description />
	<criteria>Male female subject age 18 70 year inclusive . ( NB . All female must nonreproductive potential , i.e . postmenopausal , posthysterectomy , bilateral tubal ligation bilateral oophorectomy ) . Body mass index ( BMI ) 25.0 40.0 kg/m2 ( inclusive ) . Subjects type 2 diabetes mellitus accord American Diabetes Association ( ADA ) definition duration least 3 year , stable therapy oral antidiabetic drug ( OAD ) insulin , without one two OADs glucagon like peptide1 ( GLP1 ) agonist , glitazones . Stable baseline therapy define unchanged dose regimen least 3 month administration study drug . HbA1c ≥ 6.0 ≤ 9.0 % . History hyperlipidaemia , either elevate LDL cholesterol ( &gt; 140 mg/dL ) without therapy , treatment statin ( NB . Patients statin therapy must 2 week washout enter study ) . History hypertension , either systolic blood pressure level 140 160 mmHg without treatment , treatment ACE inhibitor ARB , stable previous 3 month . Abnormal clinically significant ECG screening . Donation blood plasma past month excess 500 mL within 12 week precede screening . Intake paracetamol within 7 day start treatment . Surgery trauma significant blood loss within last 3 month administration study drug . Smokers ( negative cotinine test require ) . Clinically significant abnormal laboratory test result screen judged Investigator ( one retest within week permit , last result conclusive ) . Increased risk bleeding , e.g . subject history deep cerebral bleed know defect haemostasis increase risk bleeding , judge Investigator . History presence clinically significant disease cancer , clinically significant cardiovascular , respiratory , metabolic , renal , hepatic , gastrointestinal , endocrinological , haematological , dermatological , venereal , neurological , psychiatric disease , major disorder judge Investigator , significant secondary diabetic complication , limit clinically relevant peripheral neuropathy , retinopathy , diabetic foot ulcer , judge Investigator . Supine blood pressure screening , rest 5 min , &gt; 160 mmHg systolic &gt; 95 mmHg diastolic ( exclude whitecoat hypertension ; therefore , repeat measurement second screen visit show value within range , subject include trial ) . Type 1 diabetes mellitus . Intake antiinflammatory drug except ASA ( dose 75125mg/day stable previous 3 month ) within 14 day start treatment . Steroid therapy topical application allow . Any treatment diuretic ( hydrochlorothiazide allow ) Liver enzyme ( ALT AST ) 1.5 time upper limit normal . Any contraindication therapy ASA allergy ASA , include asthma , acute gastric ulcer , haemorrhagic diathesis , renal liver insufficiency , heart failure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacodynamics</keyword>
</DOC>